Halia Therapeutics, Inc.

?? Investing in People, Growing Together ?? At Halia Therapeutics, we believe in the power of people. Last week, our team represented Halia at the BYU BioHive Career Fair. Benjamin Bearss (Lab Manager), Devan Bursey (Biomarker Manager for Clinical Operations), and Taylor Avei (Finance and Business Development) showcased our company's commitment to growth and innovation. What makes these three remarkable? They all started as lab technicians but continued. Through dedication, adaptability, and a passion for growth, they've expanded their skill sets and taken on new roles across various departments to meet Halia's evolving needs. Their journeys exemplify our commitment to investing in our employees and fostering their career development. We’re equally committed to investing in the local biotech community. We actively participate in events like the Brigham Young University (BYU) BioHive Utah Career Fair to connect with and inspire the next generation of biotech talent. This dual focus—fostering individual growth and contributing to the broader community—is central to Halia Therapeutics' mission. We drive innovation and create meaningful impact by improving patients' lives. #CareerGrowth #InvestInPeople #BiotechCommunity #BYU #BioHive #HaliaTherapeutics

Halia Therapeutics was proud to sponsor the Regulatory & Quality Track at the Utah Life Science Summit put on yesterday by BioUtah. Our COO, Jared Bearss, kicked off the sessions, sharing Halia’s mission and highlighting the critical need for skilled regulatory and quality professionals in Utah’s growing pharma industry. We often look outside the state to fill these roles—let’s work together to build local expertise and strengthen Utah’s life sciences community! ???? #LifeSciences #Pharma #RegulatoryAffairs #QualityManagement #Utah #HaliaTx

The Future of Inflammation Treatment ?? Halia Therapeutics is pioneering inflammasome-targeting therapies, aiming to address the root of chronic inflammation in diseases like Alzheimer’s and obesity. Our CEO, Dr. David Bearss Ph.D., discusses how our work on NLRP3 inhibitors like HT-6184 could redefine treatments by safely reducing inflammation without compromising the immune defense. Read the full article here: https://lnkd.in/gP59UCCG #Inflammation #Biotech #HaliaTherapeutics #Innovation #citeline #NLRP3 #NEK7

Halia Therapeutics: Prix Galien USA Finalist! Our CEO, David Bearss, Ph.D., represented us last week at the Prix Galien USA Awards, where we were finalists in the Best Startup category. ?? Often referred as the "Nobel Prize of biomedical research," this recognition highlights our innovative biopharmaceutical research and dedication to improving patient outcomes. We're honored by this recognition and excited to continue transforming healthcare. Congratulations to Dave and the entire Halia team! ???? #PrixGalienUSA #HaliaTherapeutics #BiotechInnovation #BestStartup

A huge thank you to our track sponsors, AdvaMed, Halia Therapeutics, Inc. and Wilson Sonsini Goodrich & Rosati! Your partnership is invaluable in making the 2024 Utah Life Sciences Summit a success. Join us in Salt Lake City on November 14 to connect with industry leaders, discover the latest innovations, and hear industry-focused content curated to build the state's life sciences ecosystem. ?? Register today to secure your spot: https://lnkd.in/gQaRxP_V #UtahLifeSciencesSummit #UtahLifeSciences #BioUtah #2024ULSS #AdvaMed #HaliaTherapeutics #WilsonSonsini

Halia Therapeutics Showcases Breakthrough at Obesity Week 2024 Our CEO, Dr. David Bearss Ph.D., presented compelling data on HT-6184's impact on obesity treatment when combined with a GLP-1 agonist at Obesity Week 2024. His insights highlighted HT-6184's ability to reduce obesity-related inflammation and enhance weight loss outcomes. We're excited about HT-6184's potential for individuals struggling with obesity and our contribution to innovative obesity therapies. #HaliaTherapeutics #ObesityWeek2024 #HT6184 #ObesityResearch #Biotech #MetabolicHealth #InnovationInBiopharma

?? Dive into the future of biotech innovation with David Bearss Ph.D., Co-Founder & CEO of Halia Therapeutics, Inc., in this episode of Biotech 2050! Dr. Bearss shares how Halia is driving biotech innovation with groundbreaking genetic research aimed at addressing unmet medical needs like Alzheimer’s disease. From tackling neuroinflammation to pioneering new therapies for neurodegenerative disorders, this episode is packed with cutting-edge insights. Listen here: https://bit.ly/40u7v8p #Alzheimers #Neurodegeneration #Innovation

Halia Therapeutics to Present Groundbreaking Obesity Treatment Data at Obesity Week 2024 We're excited David Bearss Ph.D. will present groundbreaking data on HT-6184 at Obesity Week 2024 in San Antonio, Texas, from November 3-6, 2024. Our research highlights HT-6184's significant role in enhancing and sustaining weight loss when combined with a GLP-1 agonist. Using a high-fat diet model, we've demonstrated that HT-6184 reduces obesity-related inflammation. When combined with a GLP-1 agonist, it leads to improved weight loss outcomes and better lean mass retention. This promising data underscores our commitment to developing innovative therapies that tackle both the metabolic and inflammatory aspects of obesity. We're eager to engage with experts at Obesity Week and share how HT-6184 could offer a novel approach for those struggling with obesity. Read more about our upcoming presentation here: https://lnkd.in/gXdeaCMd #HaliaTx #ObesityWeek2024 #HT6184 #GLP1 #ObesityResearch #Inflammation #BiopharmaInnovation #MetabolicHealth

We're excited to announce recent discussions with M42 Health, exploring a potential partnership to transform healthcare innovation. Our CEO, David Bearss Ph.D., and COO, Jared Bearss, met with the M42 team during COP28 UAE to align our shared vision of pioneering health solutions. As we push biotech boundaries, collaborations like these open new avenues for advancing patient care and driving impactful results. Stay tuned for updates on this exciting journey! ???? #HaliaTx #M42 #HealthcareInnovation #COP28 #Partnerships #HealthTech #Biotechnology #UAE #Leadership

We were honored to welcome Ambassador Michael Ratney and the U.S. State Department team to our booth at the Global Health Exhibition 2024 in Riyadh. Their visit underscores the importance of ongoing collaboration between the United States and Saudi Arabia in healthcare and life sciences. As representatives of Halia Therapeutics, David Bearss Ph.D. Jared Bearss Margit (Maggie) Janát-Amsbury we're proud to be at the forefront of developing innovative treatments for chronic inflammation. #GlobalHealthExhibition #USSaudiCollaboration #NEK7 #NLRP3 #LRRK2 #HaliaTx